Natural History of Neuronal Ceroid Lipofuscinosis Type 6, Late Infantile Disease

被引:1
作者
O'Neal, Matthew [1 ]
de Halac, Ines Noher [2 ]
Aylward, Shawn C. [1 ,3 ]
Yildiz, Vedat [4 ,5 ]
Zapanta, Bianca [6 ]
Abreu, Nicolas [7 ]
de los Reyes, Emily [8 ]
机构
[1] Nationwide Childrens Hosp, Dept Pediat Neurol, Columbus, OH USA
[2] Natl Univ Cordoba, Cordoba, Argentina
[3] Ohio State Univ, Coll Med, Columbus, OH USA
[4] Nationwide Childrens Hosp, Biostat Resource Nationwide Childrens Hosp BRANCH, Columbus, OH USA
[5] Ohio State Univ, Coll Med, Ctr Biostat, Dept Biomed Informat, Columbus, OH USA
[6] Nationwide Childrens Hosp, Dept Pediat, Div Mol & Human Genet, Columbus, OH USA
[7] NYU, Dept Neurol, Grossman Sch Med, New York, NY USA
[8] Nationwide Childrens Hosp, 700 Childrens Dr, Columbus, OH 43205 USA
关键词
CLN6; Natural history; Batten disease; Hamburg scale; GENE-THERAPY; CLN6; SPECTRUM;
D O I
10.1016/j.pediatrneurol.2024.02.010
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Mutations in the CLN6 gene cause late infantile neuronal ceroid lipofuscinosis, a neurodegenerative lysosomal storage disease of childhood onset. Clinically, individuals present with progressive motor and cognitive regression, ataxia, and early death. The aim of this study is to establish natural history data of individuals with classic, late-infantile-onset (age less than five years) CLN6 disease. Methods: We analyzed the natural history of 25 patients with late-infantile-onset CLN6, utilizing the Hamburg motor-language scale to measure disease progression. The key outcomes were CLN6 disease progression, assessed by rate of decline in motor and language clinical domain summary scores (0 to 6 total points); onset and type of first symptom; onset of first seizure; and time from first symptom to complete loss of function. Results: Median age of total motor and language onset of decline was 42 months (interquartile range 36 to 48). The estimated rate of decline in total score was at a slope of -1.20 (S.D. 0.30) per year, after the start of decline. Complete loss of both motor and language function was found to be, on average, 88.1 months (S.D. 13.5). Conclusions: To our knowledge, this is the largest international study that monitors the longitudinal natural history and progression of CLN6 disease. These data may serve as a template for future interventional trials targeted to slow the progression of this devastating disease. (c) 2024 Elsevier Inc. All rights reserved.
引用
收藏
页码:51 / 57
页数:7
相关论文
共 16 条
  • [1] Neuronal Ceroid Lipofuscinosis Type 6 (CLN6) clinical findings and molecular diagnosis: Costa Rica's experience
    Badilla-Porras, R.
    Echeverri-McCandless, A.
    Weimer, J. M.
    Ulate-Campos, A.
    Soto-Rodriguez, A.
    Gutierrez-Mata, A.
    Hernandez-Con, L.
    Bogantes-Ledezma, S.
    Balmaceda-Meza, A.
    Brudvig, J.
    Sanabria-Castro, A.
    [J]. ORPHANET JOURNAL OF RARE DISEASES, 2022, 17 (01)
  • [2] Moving towards a new era of genomics in the neuronal ceroid lipofuscinoses
    Butz, Elisabeth S.
    Chandrachud, Uma
    Mole, Sara E.
    Cotman, Susan L.
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2020, 1866 (09):
  • [3] Electroclinical spectrum of the neuronal ceroid lipofuscinoses associated with CLN6 mutations
    Canafoglia, Laura
    Gilioli, Isabella
    Invernizzi, Federica
    Sofia, Vito
    Fugnanesi, Valeria
    Morbin, Michela
    Chiapparini, Luisa
    Granata, Tiziana
    Binelli, Simona
    Scaioli, Vidmer
    Garavaglia, Barbara
    Nardocci, Nardo
    Berkovic, Samuel F.
    Franceschetti, Silvana
    [J]. NEUROLOGY, 2015, 85 (04) : 316 - 324
  • [4] Variant late infantile ceroid lipofuscinoses associated with novel mutations in CLN6
    Cannelli, Natalia
    Garavaglia, Barbara
    Simonati, Alessandro
    Aiello, Chiara
    Barzaghi, Chiara
    Pezzini, Francesco
    Cilio, Maria Roberta
    Biancheri, Roberta
    Morbin, Michela
    Bernardina, Bernardo Dalla
    Granata, Tiziana
    Tessa, Alessandra
    Invernizzi, Federica
    Pessagno, Alice
    Boldrini, Renata
    Zibordi, Federica
    Grazian, Luisa
    Claps, Dianela
    Carrozzo, Rosalba
    Mole, Sara E.
    Nardocci, Nardo
    Santorelli, Filippo M.
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2009, 379 (04) : 892 - 897
  • [5] NEURODEGENERATIVE DISEASES OF INFANCY AND CHILDHOOD
    DYKEN, P
    KRAWIECKI, N
    [J]. ANNALS OF NEUROLOGY, 1983, 13 (04) : 351 - 364
  • [6] THE NEURONAL CEROID LIPOFUSCINOSES
    DYKEN, PR
    [J]. JOURNAL OF CHILD NEUROLOGY, 1989, 4 (03) : 165 - 174
  • [7] Fumagalli F, 2022, LANCET, V399, P372, DOI 10.1016/S0140-6736(21)02017-1
  • [8] Natural history of diseases: Statistical designs and issues
    Jewell, Nicholas P.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 100 (04) : 353 - 361
  • [9] Current Clinical Applications of In Vivo Gene Therapy with AAVs
    Mendell, Jerry R.
    Al-Zaidy, Samiah A.
    Rodino-Klapac, Louise R.
    Goodspeed, Kimberly
    Gray, Steven J.
    Kay, Christine N.
    Boye, Sanford L.
    Boye, Shannon E.
    George, Lindsey A.
    Salabarria, Stephanie
    Corti, Manuela
    Byrne, Barry J.
    Tremblay, Jacques P.
    [J]. MOLECULAR THERAPY, 2021, 29 (02) : 464 - 488
  • [10] CLN6, which is associated with a lysosomal storage disease, is an endoplasmic reticulum protein
    Mole, SE
    Michaux, G
    Codlin, S
    Wheeler, RB
    Sharp, JD
    Cutler, DF
    [J]. EXPERIMENTAL CELL RESEARCH, 2004, 298 (02) : 399 - 406